A detailed history of First Republic Investment Management, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 10,000 shares of ACAD stock, worth $170,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Previous 11,058 9.57%
Holding current value
$170,700
Previous $264,000 21.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$20.84 - $33.47 $22,048 - $35,411
-1,058 Reduced 9.57%
10,000 $208,000
Q2 2023

Jul 28, 2023

SELL
$17.8 - $25.65 $61,321 - $88,364
-3,445 Reduced 23.75%
11,058 $264,000
Q1 2023

May 11, 2023

SELL
$16.32 - $20.92 $9,498 - $12,175
-582 Reduced 3.86%
14,503 $272,000
Q4 2022

Feb 13, 2023

BUY
$14.2 - $18.63 $214,207 - $281,033
15,085 New
15,085 $240,000
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $327,250 - $429,770
-15,628 Closed
0 $0
Q4 2021

Feb 09, 2022

SELL
$16.79 - $27.09 $18,720 - $30,205
-1,115 Reduced 6.66%
15,628 $365,000
Q3 2021

Nov 12, 2021

SELL
$15.78 - $24.77 $962 - $1,510
-61 Reduced 0.36%
16,743 $278,000
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $31,835 - $44,996
-1,641 Reduced 8.9%
16,804 $410,000
Q1 2021

May 14, 2021

BUY
$25.02 - $54.99 $216,548 - $475,938
8,655 Added 88.41%
18,445 $476,000
Q4 2020

Feb 16, 2021

BUY
$41.04 - $56.79 $9,357 - $12,948
228 Added 2.38%
9,790 $523,000
Q3 2020

Nov 12, 2020

BUY
$36.42 - $57.0 $41,008 - $64,182
1,126 Added 13.35%
9,562 $394,000
Q2 2020

Aug 13, 2020

BUY
$39.26 - $52.73 $1,531 - $2,056
39 Added 0.46%
8,436 $409,000
Q1 2020

May 13, 2020

BUY
$31.65 - $46.87 $265,765 - $393,567
8,397 New
8,397 $355,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.